Shots:

• The approval was based on the P-III (HELP) study, P-III (HELP) OLE study along with the results from the P-III study evaluating Takhzyro (300mg, q2w, SC) in Japanese patients aged ≥12yrs. with prophylaxis against acute attacks of HAE
• The results showed the efficacy & safety profile of Takhzyro as a preventive treatment for HAE attacks across all studies. In a Japan-specific P-III study, 41.7% of patients did not develop attacks during the efficacy evaluation period @26wks. after SC administration of Takhzyro
• Takhzyro has been approved in the US & EU for HAE attacks in patients aged ≥12yrs. in 2018 & is approved in 50+ countries. The therapy has been supported by a clinical development program

Ref: Takeda | Image: Takeda